http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Dok Hyun Yoon(윤덕현),Yoojin Cho(조유진),Ji Youn Kim(김지연),Sang Yoon Kim(김상윤),Soon Yuhl Nam(남순열),Seung-Ho Choi(최승호),Jong-Lyel Roh(노종렬),Sang-Wook Lee(이상욱),Jeong Hyun Lee(이정현),Jae Seung Kim(김재승),Kyung-Ja Cho(조 대한두경부종양학회 2011 대한두경부 종양학회지 Vol.27 No.2
서 론 5-FU와 cisplatin 병용항암화학요법은 국소진행성 두경부편평상피암의 유도화학요법으로 널리 사용되고 있는 요법이다. 저자들은 5-FU 대신 경구제재인 S-1을 cisplatin과 병용하는 복합항암요법의 효과와 안전성에 대해 연구하였다. 대상 및 방법 저자들은 2007년 2월부터 2008년 12월까지 S1과 cisplatin의 복합유도화학요법을 시행받은 3/4기 구인두, 하인두, 후두, 구강 편평상피세포암 환자 52명의 치료결과를 후향적으로 분석하였다. 유도항암화학요법은 제 1일에 cisplatin(75 또는 60mg/m 2 ), 제1일부터 14일까지 S-1(40mg/m 2 )을 1일 2회, 21일 간격으로 투여하였고 가능한 경우에는 항암방사선동시요법 또는 수술을 뒤이어 시행하였다. 결 과 전체 52명 중 37명(71.2%)에서 부분반응을 보였으나 완전반응은 관찰되지 않았다. 2년 무진행생존율은 56.9%, 2년 전체생존율은 68.2%였다. 유도항암요법과 관련된 유해반응으로는 호중구감소증(71.2%) 및 빈혈(63.5%) 등과 같은 혈액학적 부작용이 가장 흔했다. 결 론 S-1과 cisplatin의 복합항암화학요법은 국소진행성 두경부편평상피암 환자를 대상으로 한 유도화학요법으로 적용이 가능한 것으로 판단된다.
Yoon, Dok Hyun,Shin, Jae-Sik,Jin, Dong-Hoon,Hong, Seung-Woo,Jung, Kyung A,Kim, Seung-Mi,Hong, Yong Sang,Kim, Kyu-Pyo,Lee, Jae-Lyun,Suh, Cheolwon,Lee, Jung Shin,Kim, Tae Won Potamitis Press 2012 Anticancer research Vol.32 No.5
<P>Survivin is a negative regulator of apoptosis. We evaluated the efficacy of YM155, a selective suppressant of survivin, in combination with gemcitabine in the pancreatic cancer cell line MiaPaCa-2.</P>
( Ji Hyun Park ),( Dok Hyun Yoon ),( Shin Kim ),( Jin Sook Ryu ),( Sang Wook Lee ),( Chan Sik Park ),( Joo Ryung Huh ),( Cheol Won Suh ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Despite its predictive role is well established in several aggressive types of lymphomas, clinical utility of positron emission tomography-computed tomography (PET-CT) scans in marginal zone lymphoma (MZL) remains yet unclear. Hence, we investigated whether PET-CT scans might also predict clinical courses in patients with MZL who underwent induction chemotherapy, Methods: A total of 32 MZL patients who underwent induction chemotherapy with comparable baseline, interim, and post-treatment PET-CT scans were enrolled. The primary endpoint was to compare event-free survival (EFS) by achievement of metabolic complete response (mCR) in post-treatment PET-CT scans. The secondary endpoint was to determine whether mCR in interim PET-CT or early metabolic responder, who achieved mCR since interim PET-CT, could predict more favorable EFS Results: Compared with non-mCR group, 5-year EFS was signifi cantly superior in patients who achieved mCR in interim PET-CT scans (70.6% VS 13.1%, p=0.007) as well as in post-treatment PET-CT (55.0% VS 0.0%p =0.010). Moreover, early metabolic responder showed more favorable 5-year EFS to patients with delayed or never achievement of mCR (70.6% VS 22.5% VS 0%, p=0.011). In addition, patients with high SUV showed strong trends of inferior EFS and OS with marginal statistical signifi cance (p= 0.072, and p=0.101, respectively). Conclusions: Achievement of mCR in interim as well as post-treatment PET-CT seems to well predict more favorable EFS in patients with MZL after induction chemotherapy. Moreover, earlier achieved mCR since interim PET-CT might be an independent predictor of superior 5-year EFS in these patients.
장근두,Dok Hyun Yoon,Shin Kim,이대호,이상욱,허주령,서철원 대한혈액학회 2011 Blood Research Vol.46 No.2
Background :The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been established. We aimed to evaluate the impact of R-CHOP compared with CHOP in patients with DLBCL and to establish clinical predictors of better outcomes in these patients. Methods :We retrospectively identified 177 patients diagnosed with CD20-positive DLBCL and treated with CHOP (N=82) or R-CHOP (N=95). The response rate, event-free survival (EFS), and overall survival (OS) rates were compared between the 2 treatment groups. All patients were classified into primary extranodal lymphoma (PENL) or nodal lymphoma (NL) subgroups, and the clinical parameters of each subgroup were analyzed. Results :The overall response rate was higher in R-CHOP group (95% vs. 84%, P=0.07). The 3-year EFS rate was significantly higher in R-CHOP group (71% vs. 52%, P=0.013), but the OS rate was comparable between the 2 groups (79% vs. 69%, P=0.23). A significant survival benefit was seen with R-CHOP compared to CHOP therapy in NL patients (P=0.002 for EFS and 0.04 for OS). Multivariate analyses confirmed that R-CHOP therapy is an independent prognostic factor for EFS (hazard ratio of 0.32 [0.17-0.62], P=0.001) and OS (hazard ratio of 0.4 [0.18-0.87], P=0.02) in NL patients. Conclusion :Patients in the PENL group did not benefit from R-CHOP chemotherapy.
( Changhoon Yoo ),( Dok Hyun Yoon ),( Shin Kim ),( Chan Sik Park ),( Jooryung Huh ),( Sang Wook Lee ),( Jung Sun Park ),( Cheolwon Suh ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Although serum Beta-2 microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, this was rarely investigated in marginal zone lymphoma (NZL). Materials: Between January, 2000, and May, 2013, a total of 270 patients with non-gastric (NG)-MZL were identified from database of Asan Medical Center, Seoul, Korea. Among them, pretreatment baseline serum B2M was available in 204 patients. Progression-free survival (PFS) and overall survival (OS) were compared according to the level of B2M with cut-off value of 2.5 mg/L. Results: Median age of study population was 51 year-old (range, 16-81) and 85 (42%) patients were male. Thirty (15%) patients had nodal MZL and 174 (85%) had extranodal MALToma. B2M =2.5 mg/L was related with more adverse clinical features, such as poor performance status, =2 extranodal sites, advanced stage (III-IV), anemia, elevated LDH, bone marrow invasion, and higher IPI risk group. In univariate analysis, serum B2M (<2.5 mg/L vs =2.5 mg/L) was significantly associated with PFS (p<0.001) and OS (p<0.001). In multivariate analysis including B2M and International Prognostic Index (IPI), serum B2M =2.5 mg/L was an independent adverse prognostic factor in terms of PFS (hazard ratio [HR]=3.7, 95% CI, 1.5-9.1; p=0.005) and OS (HR=7.5, 95% CI, 1.7-32.7; p=0.008). In analysis including Korean MZL Prognostic Index (MZLPI: nodal MZL, ECOG performance status =2 and advanced stage), B2MG =2.5 mg/L was also significant for PFS (HR=3.5, 95% CI, 1.5-7.7; p=0.003) and OS (HR=7.3, 95% CI 1.9- 28.2; p=0.004). Conclusion: In patients with NG-MZL, baseline serum B2M is a powerful prognostic factor for PFS and OS, independent of validated prognostic indexes, such as MZLPI and IPI.